Jinarc (Tolvaptan)
tolvaptan 30 mg tablet [28] (&) tolvaptan 60 mg tablet [28], 56 · ORAL · PBS code 11597J
AUTHORITY_REQUIREDWhat it costs
AU$498.75 PBS-determined price per 1 units
Most patients pay only the standard PBS co-payment, not the full price above — up to AU$25.00 per script (general) or AU$7.70 (concession/Safety Net) in 2026. The figure above is what the PBS pays the pharmacy; the Australian Government subsidises the rest. Always confirm the current amount with your pharmacist.
- • First listed on the PBS: 2019-01-01.
- • Repeats: 5.
- • PBS program: GE.
Eligibility criteria for subsidised access
The following is the government's own wording from the PBS Schedule, shown unchanged.
Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1
Autosomal dominant polycystic kidney disease (ADPKD)
Initial treatment
Must be treated by a nephrologist; AND
Patient must have an estimated glomerular filtration rate (eGFR) between 30 and 89 mL/min 1.73 m2 at the initiation of treatment with this drug for this condition; AND
Patient must have or have had rapidly progressing disease at the time of initiation of this drug for this condition.
Rapidly progressing disease is defined as either of the following:
A decline in eGFR of greater than or equal to 5 mL/min/1.73 m2 within one year;
OR
An average decline in eGFR of greater than or equal to 2.5 mL/min/1.73 m2 per year over a five year period.
Sponsor: Otsuka Australia Pharmaceutical Pty. Ltd ABN 20 601 768 754
Not medical advice. Voxsanity republishes public PBS data in plain English. PBS listing status and criteria can change; always confirm current subsidised availability with your doctor or pharmacist.
Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.